Speech-Language Pathologists in St. Albans, NY Accepting Medicare
3 Speech-Language Pathologists found. Showing 1 - 3
 Mrs. Jasmine L. Eaglin, M.S., CCC-SLP, TSSLD Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 114-36 202nd Street, Mini Building, St. Albans, NY 11412 Phone: 718-776-4500 |
Shira E Kirschner, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 172-17 Linden Blvd, St. Albans, NY 11434 Phone: 718-657-1024 Fax: 718-291-4876 |
 David Francis Brooks, MA-CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 179 Street And Linden Blvd, St. Albans, NY 11425 Phone: 718-526-1000 |
News Archive
Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today released data showing that its gene therapy Glybera® (alipogene tiparvovec) significantly reduces the risk of pancreatitis in patients with Lipoprotein Lipase Deficiency (LPLD). Pancreatitis, or inflammation of the pancreas, is a major clinical symptom of LPLD.
Midday naps linked to reduced blood pressure levels, fewer antihypertensive medications
Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress today by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece.
Study finds anti-gout medication may reduce risk of colorectal cancer
Allopurinol, a relatively inexpensive anti-gout medication that has been on the market for more than 20 years, may have some activity against colorectal adenomas, according to data presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held here Nov. 7-10, 2010.
Genetic test may help identify better treatment option for HER2-positive breast cancer patients
A genetic test for PIK3CA mutations may help to identify patients with HER2-positive breast cancer who are less likely to benefit from combination anti-HER2 therapy, according to a study published in The Oncologist on August 5, 2015.
SANUWAVE Health raises $4,102,660 from exercise of Options
SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, announces that it has raised gross proceeds of $4,102,660 from the exercise of Options that were issued as part of the sale of Units to accredited investors during 2010. The Options had an expiration date of January 31, 2011.
› Verified 1 days ago
Occupational Therapists
Physical Therapists
Speech-Language Pathologists
Audiologists